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Abstract
Background—Age-related cataract is a major cause of visual impairment in the elderly. 
Oxidative stress has been implicated in its formation and progression. Antioxidant vitamin 
supplementation has been investigated in this context.
Objectives—To assess the effectiveness of antioxidant vitamin supplementation in preventing 
and slowing the progression of age-related cataract.
Search methods—We searched CENTRAL (which contains the Cochrane Eyes and Vision 
Group Trials Register) (The Cochrane Library 2012, Issue 2), MEDLINE (January 1950 to March 
2012), EMBASE (January 1980 to March 2012), Latin American and Caribbean Literature on 
Health Sciences (LILACS) (January 1982 to March 2012), Open Grey (System for Information on 
Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) 
(www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO 
International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). There 
were no date or language restrictions in the electronic searches for trials. The electronic databases 
were last searched on 2 March 2012. We also checked the reference lists of included studies and 
ongoing trials and contacted investigators to identify eligible randomized trials.
Selection criteria—We included only randomized controlled trials in which supplementation 
with one or more antioxidant vitamins (beta-carotene, vitamin C and vitamin E) in any form, 
dosage or combination for at least one year was compared to another antioxidant vitamin or to 
placebo.
Data collection and analysis—Two authors extracted data and assessed trial quality 
independently. We pooled results for the primary outcomes, i.e., incidence of cataract and 
incidence of cataract extraction. We did not pool results of the secondary outcomes - progression 
of cataract and loss of visual acuity, because of differences in definitions of outcomes and data 
presentation. We pooled results by type of cataract when data were available. We did not perform 
a sensitivity analysis.
Main results—Nine trials involving 117,272 individuals of age 35 years or older are included in 
this review. The trials were conducted in Australia, Finland, India, Italy, the United Kingdom and 
the United States, with duration of follow-up ranging from 2.1 to 12 years. The doses of 
antioxidant vitamins were higher than the recommended daily allowance. There was no evidence 
of effect of antioxidant vitamin supplementation in reducing the risk of cataract, cataract 
extraction, progression of cataract or in slowing the loss of visual acuity. In the pooled analyses, 
there was no evidence of effect of beta-carotene supplementation in reducing the risk of cataract 
(two trials) (relative risk (RR) 0.99, 95% confidence interval (CI) 0.91 to 1.08; n = 57,703) or in 
reducing the risk of cataract extraction (three trials) (RR 1.00, 95% CI 0.91 to 1.10; n = 86,836) or 
of vitamin E supplementation in reducing the risk of cataract (three trials) (RR 0.97, 95% CI 0.91 
to 1.04; n = 50,059) or of cataract extraction (five trials) (RR 0.98, 95% CI 0.91 to 1.05; n = 
83,956). The proportion of participants developing hypercarotenodermia (yellowing of skin) while 
on beta-carotene ranged from 7.4% to 15.8%.
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Authors’ conclusions—There is no evidence from RCTs that supplementation with 
antioxidant vitamins (beta-carotene, vitamin C or vitamin E) prevents or slows the progression of 
age-related cataract. We do not recommend any further studies to examine the role of antioxidant 
vitamins beta-carotene, vitamin C and vitamin E in preventing or slowing the progression of age-
related cataract. Costs and adverse effects should be weighed carefully with unproven benefits 
before recommending their intake above recommended daily allowances.
PLAIN LANGUAGE SUMMARY
Antioxidant vitamins for preventing and slowing the progression of age-related cataract
A cataract occurs when the normally clear lens in the eye becomes cloudy. Cataracts are the 
leading cause of correctable reduced vision worldwide. Most cataracts develop slowly with 
normal aging. However, cataracts also may be related to genetic diseases and medical 
conditions such as diabetes. Other factors such as poor nutrition, sun damage, radiation, 
corticosteroids, smoking, alcohol, eye trauma or other eye surgery may influence cataract 
formation.
Mild or early cataracts may not impair vision. In some cataracts, new eye-glass 
prescriptions, brighter lighting or magnifying lenses may overcome the vision losses. When 
these interventions fail to improve poor vision due to cataracts, surgical removal (extraction) 
is the generally accepted effective treatment. However, cataract surgery is associated with 
some risks. The estimated annual costs for outpatient, inpatient and prescription drug 
services related to the treatment of cataract is USD 6.8 billion.
Antioxidant vitamin supplementation has been studied as a means to prevent the formation 
or to slow the progression of cataract. Results from observational studies have been 
inconsistent.
The review authors searched for randomized controlled trials in which supplementation with 
the antioxidant vitamins beta-carotene (provitamin A), vitamin C and vitamin E was 
compared to inactive placebo or no supplement. Nine trials involving 117,272 adults of age 
35 years or older were included in this review. The trials were conducted in Australia, 
Finland, India, Italy, the United Kingdom and the United States and were of high 
methodological quality. The doses of antioxidants given in each trial were higher than the 
recommended daily allowances. The trials provided no evidence of effect of the antioxidant 
vitamins beta-carotene, vitamin E and vitamin C given alone or in combination on the 
incidence of cataract, its extraction or progression and on the loss of visual acuity. Some 
participants (7% to 16%) on beta-carotene developed yellowing of the skin 
(hypercarotenodermia).
BACKGROUND
Description of the condition
Introduction—Cataract is the opacification of the normally transparent lens in the eye. 
Cataracts might be congenital or hereditary, associated with certain risk factors and systemic 
diseases, or caused by toxins and drugs or physical trauma.
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Most cataracts develop slowly as a consequence of aging. The pathogenesis of age-related 
cataract is multifactorial and not completely understood. Important risk factors in addition to 
age include diabetes mellitus, exposure to ultraviolet radiation, use of corticosteroids and 
recreational drugs such as nicotine and alcohol. The formation of cataract is accelerated in 
ocular trauma, vitreoretinal surgery, uveitis and diabetes mellitus. Oxidation reactions in the 
lens, both as a consequence to normal aging and those triggered by UV radiation, are 
believed to be potent etiological factors in the development of cataract (Abraham 2006; 
West 1995).
The earliest opacities may appear anywhere within the body of the lens; the processes that 
culminate in poor vision vary depending upon the site of initiation. Thus, age-related 
cataract is classified into three major types: nuclear, cortical and posterior subcapsular. 
Among these, cigarette smoking has been linked with nuclear cataract whereas 
corticosteroid use and trauma have been linked with posterior subcapsular cataract (Wevill 
2008).
Epidemiology—Age-related cataract is the leading cause of blindness in the world. It 
accounts for 17.7 million (47.8%) of the total 37 million cases worldwide. It is even more 
significant as a cause of low vision and is the leading cause of low vision in all the World 
Health Organization sub-regions (GDVI 2004). In the United States, an estimated 20.5 
million (17.2%) people older than 40 years have cataract in one or both eyes, with the 
prevalence expected to rise by 50% to 30.1 million in 2020 (Congdon 2004).
Women have a higher risk of being visually impaired than men. The worldwide prevalence 
ratio of female to male visual impairment ranges from 1.5 to 2.2 (GDVI 2004). In the United 
States, women have higher age-adjusted prevalence of cataract than men (Congdon 2004). 
The odds of cataract were 75% (odds ratio (OR) 1.75, 95% confidence interval (CI) 1.18 to 
2.56) and 35% (OR 1.35, 95%CI 1.23 to 1.49) higher among black and white women 
respectively when compared to men (Congdon 2004). The prevalence increases with age and 
the overall global burden is expected to rise with increases in life expectancy.
Costs—Recent data on the costs related to management of cataract worldwide are 
unavailable. In the United States, healthcare costs for individuals over age 65 are partially 
covered by Medicare. Cataract surgery, IOL implantation, and other cataract-related costs 
amount to about 60%of all Medicare expenditures related to vision (Ellwein 2002). It is 
estimated that the direct annual medical costs for outpatient, inpatient and prescription drug 
services related to the treatment of cataract total USD 6.8 billion (PBA 2008).
Interventions for cataract—The symptoms of early cataract can possibly be improved 
with the use of new eyeglasses, brighter lighting, anti-glare glasses or magnifying lenses. 
However, surgical extraction is the only effective treatment for cataract (Leyland 2006; Riaz 
2006). There are no medications, eye drops, exercises or glasses that have been proven to be 
effective in preventing the formation or slowing the progression of cataract in the otherwise 
healthy aging adult eye.
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Description of the intervention—Supplementation with vitamins with antioxidant 
properties such as beta-carotene and vitamins C and E have been proposed as candidate 
interventions to prevent or slow progression of cataract. Beta-carotene is a red-orange fat-
soluble compound abundant in fruits such as mangoes, papayas, carrots and yams and in 
green leafy vegetables such as spinach, kale and leaves of sweet potato and sweet gourd. It 
is a provitamin converted by the body to active vitamin A which has antioxidant properties. 
Vitamin A plays an important role in vision and is also needed for bone development, 
testicular and ovarian function, embryonic development and maintenance of mucosal and 
epithelial surfaces. The recommended dietary allowance (RDA) for adults has been 
established by the U.S. Institute of Medicine of the National Academy of Sciences. There 
are no RDA for beta-carotene. The RDA for vitamin A is 900 micrograms retinol (3000 
International Units (IU)) for adult males and 700 micrograms retinol (2300 IU) for adult 
females. One microgram of retinol is equivalent to one Retinol Activity Equivalents (RAE). 
One RAE is equivalent to 2 micrograms all-trans-beta-carotene as a supplement or 12 
micrograms of all-trans-beta-carotene in the diet. Deficiency of vitamin A can cause night 
blindness, xerophthalmia (dry eyes), dermatological problems and impairment of immune 
response.
Vitamin C is a water-soluble compound present in milk and animal products such as liver 
and fish; vitamin C is abundant in vegetables and fruits, especially citrus fruits such as 
oranges. It is important in the synthesis of collagen and carnitine and for neurotransmitter 
and cholesterol metabolism; it has antioxidant properties. The RDA for vitamin C is 90 mg 
for adult males and 75 mg for adult females. Deficiency of vitamin C causes scurvy.
Vitamin E is a fat-soluble compound found in a variety of foods including oils, meat, eggs 
and leafy vegetables. Vitamin E has antioxidant properties and works as a free radical 
scavenger, protecting polyunsaturated fatty acids (PUFA), a major structural component of 
the cell membranes, from peroxidation. The RDA for vitamin E is 15 mg (22.4 IU) for 
adolescents and adults. Deficiency of vitamin E can cause neuromuscular disorders, lysis of 
red blood cells and impairment of immune response.
How the intervention might work—Oxidation of lens proteins and mitochondrial 
function are key factors in cataract pathogenesis (Wevill 2008). Beta-carotene is known to 
be an effective antioxidant at low partial pressures of oxygen, as exists in the lens (Burton 
1984). Vitamin C is located in the aqueous compartments of lens membranes where it may 
function as an antioxidant and protect enzymes in the lens from photo-oxidative destruction 
(Blondin 1986). Vitamin E is lipid soluble and concentrated in the lens fibers and 
membranes and may inhibit cataract formation by reducing photo-peroxidation of lens lipids 
and by stabilizing lens cell membranes (Karslioglu 2004; Libondi 1985; Ohta 1996; Varma 
1982).
Why it is important to do this review—Laboratory and epidemiologic evidence linking 
oxidative stress to cataract formation have led investigators to assess the role of antioxidant 
intake in the development of age-related cataract. Several observational studies have noted 
protective associations for various antioxidants. However, in totality, the evidence from the 
large number of observational studies that have examined this association (Brown 1999; 
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Chasan-Taber 1999; Cumming 2000; Hankinson 1992; IACS 1991; Jacques 1988; Jacques 
1991; Jacques 1997; Jacques 2001; Knekt 1992; Kuzniarz 2001; Leske 1991; Leske 1995; 
Leske 1997; Leske 1998; Lyle 1999; Mares-Perlman 1994; Mares-Perlman 1995; Mares-
Perlman 2000;McCarty 1999;Milton 2006;Mohan 1989; Nadalin 1999; Robertson 1989; 
Robertson 1991; Rouhiainen 1996; Seddon 1994; Tavani 1996; Taylor 2002; Vitale 1993; 
Yoshida 2007) is inconsistent. The possibility of biases and unadjusted confounding in these 
observational studies provided the rationale for randomized controlled trials to examine this 
association. However, there are no known systematic reviews that have examined the role of 
antioxidant vitamin supplementation in preventing or slowing the progression of age-related 
cataract.
OBJECTIVES
To assess the effectiveness of antioxidant vitamin supplementation, specifically beta-
carotene, vitamin C and vitamin E, in preventing and slowing the progression of age-related 
cataract.
METHODS
Criteria for considering studies for this review
Types of studies—We included randomized controlled trials with a minimum follow-up 
of one year.
Types of participants—We included trials of participants irrespective of demographic 
characteristics or co-morbidities.
Types of interventions—We included randomized controlled trials in which 
supplementation with one or more antioxidant vitamins, specifically beta-carotene, vitamin 
C and vitamin E in any form, dosage or combination, for at least one year was compared to 
another antioxidant vitamin, to placebo or to no supplementation.
Types of outcome measures
Primary outcomes
1. Incidence of cataract as defined by the included studies
2. Incidence of cataract extraction: defined as surgery to remove a visually significant 
lens opacity. The determination of visually significant was as defined by the 
included studies
Secondary outcomes
1. Progression of cataract: we used any well-defined measure of progression 
depending on the way authors presented trial data.
2. Loss of vision: we used any well-defined measure of visual acuity depending on the 
way authors presented trial data.
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Adverse effects: We report the adverse effects of beta-carotene and vitamin E 
supplementation.
Search methods for identification of studies
Electronic searches—We searched the Cochrane Central Register of Controlled Trials 
(CENTRAL) 2012, Issue 2, part of The Cochrane Library. www.thecochranelibrary.com 
(accessed 2 March 2012), MEDLINE (January 1950 to March 2012), EMBASE (January 
1980 to March 2012), Latin American and Caribbean Literature on Health Sciences 
(LILACS) (January 1982 to March 2012), Open Grey (System for Information on Grey 
Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) 
(www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO 
International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). 
There were no language or date restrictions in the search for trials. The electronic databases 
were last searched on 2 March 2012. See: Appendices for details of search strategies for 
CENTRAL (Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix 3), LILACS 
(Appendix 4), OpenGrey (Appendix 5), mRCT (Appendix 6), ClinicalTrials.gov (Appendix 
7) and the ICTRP (Appendix 8).
Searching other resources—We searched the reference lists of included studies and 
ongoing trials to identify additional trials. We used the Science Citation Index to identify 
trials that referenced these trials. We contacted the investigators of the included trials for 
information on additional and unreported trials.
Data collection and analysis
Selection of studies—We independently screened the titles and abstracts obtained by the 
searches. We obtained and assessed the full-text copies of reports from probable or 
definitely relevant trials as per the ’Criteria for considering studies for this review’ section. 
We assessed all articles that met the inclusion criteria for methodological quality.
Data extraction and management—Two review authors independently extracted data 
using a form developed by the Cochrane Eyes and Vision Group. One review author entered 
data into RevMan 5 (Review Manager 2011) and a second author verified all values.
Assessment of study characteristics—We extracted information on the following 
study characteristics:
• Methods: study design; method of randomization; unit of randomization 
(individuals/eyes); method of allocation concealment; number randomized; 
exclusions after randomization; number analyzed; masking (blinding); losses to 
follow-up; unit of analysis (individuals/eyes).
• Participants: country; age; gender; inclusion/exclusion criteria.
• Interventions: treatment (including dose and schedule); control; duration of 
treatment; length of follow-up (planned/actual); compliance.
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• Outcomes: relevant outcomes (definition, method of assessment, statistical 
methods used); eye examined or the outcome (worse/better/average); intervals at 
which each outcome was assessed; quality control for outcome assessment; adverse 
effects.
• Notes: study period; general health status of study population; types of subgroup 
analyses; control group event rate for dichotomous outcomes; power calculation 
(Yes/No, if yes whether appropriate); quality of life indicators; funding sources.
Assessment of risk of bias in included studies—Two authors independently 
assessed included trials for sources of systematic bias according to the guidelines in Chapter 
8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We 
evaluated the trials for the following criteria: sequence generation and allocation 
concealment (selection bias),masking of care providers and recipients of care (performance 
bias), masking of outcome assessors (detection bias), incomplete outcome data (attrition 
bias), selective outcome reporting (reporting bias) and other sources of bias (intention-to-
treat analysis, equivalence of baseline characteristics and adherence to treatment). We 
reported the judgment for each criterion as low risk of bias, high risk of bias or unclear 
(information is insufficient to assess). We resolved disagreements through discussion. We 
contacted authors of the trials for additional information on issues that were unclear based 
on information available in the original report. In case of failure to communicate with the 
primary investigators, or if there was no response within six weeks, we assessed the 
methodological quality on the basis of the available information.
Measures of treatment effect—We extracted Cox proportional hazard ratios, 
unadjusted risk ratios and numbers and percentages for primary outcomes and difference in 
slope, adjusted and unadjusted odds ratios, unadjusted risk ratios, mean of last value and 
mean change from baseline for secondary outcomes.
For PHS II 2010, we calculated the Mantel-Haenszel risk ratio with 95% confidence limits 
for incidence of cataract. For AREDS 2001, we calculated relative risks and 95% confidence 
limits (from 99% confidence intervals) for incidence of cataract extraction. For VECAT 
2004, we calculated incidence of cataract extraction from values in the published study. For 
PPP 2001, we calculated incidence of cataract extraction from values obtained through 
personal communication. We used RevMan 5 to perform these calculations. Minor 
discrepancies at the second decimal place occurred with these data transformations.
Unit of analysis issues—The unit of analysis was the individual in all studies included 
in this review.
Dealing with missing data—We contacted primary authors of included trials for study 
methods and outcomes that were missing or not reported. We calculated relative risks (RR) 
and 95% confidence intervals (CI). We did not impute data.
Assessment of heterogeneity—We examined included trials for clinical heterogeneity 
by type of antioxidant, and by participant age, gender and country of origin. We did not pool 
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results across antioxidant vitamin groups because of differences in their clinical properties. 
We examined statistical heterogeneity using the Chi2 test and I2 statistic.
Assessment of reporting biases—Although we planned to examine a funnel plot in 
conjunction with study characteristics or other factors that may contribute to asymmetry of 
the funnel plot to assess reporting biases, we chose not to include a funnel plot due to the 
limited number of included studies.
Data synthesis—We calculated summary relative risks for the incidence of cataract and 
cataract extraction, using the generic inverse variance method (fixed-effect model).
We did not pool results for the secondary outcomes because of differences in the definition 
of the outcomes as well as appreciable variability in the analysis and presentation of data. In 
such instances and in cases where only summary data or adjusted estimates were presented 
in the trial report, we used ’Other data tables’ for presenting data.
Subgroup analysis and investigation of heterogeneity—We did not plan any 
subgroup analyses. However, we performed subgroup analysis by type of cataract (cortical, 
nuclear and posterior subcapsular) in instances where the data were available from the 
published report.
Sensitivity analysis—We planned to conduct sensitivity analyses by excluding trials that 
were at high risk of bias. As the majority of the trials that were pooled were large trials of 
high methodological quality, we did not conduct sensitivity analysis.
RESULTS
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics 
of ongoing studies.
We describe the trials assessed for inclusion and exclusion in the ’Characteristics of 
included studies’ and ’Characteristics of excluded studies’ tables.
Results of the search
Selection of trials: We conducted electronic searches which yielded a total of 1861 reports 
of trials (Figure 1). We conducted manual searches of included and ongoing trials and also 
contacted study authors for information on other completed or ongoing trials. We screened 
titles and abstracts as per the inclusion criteria. We evaluated the full text of 31 reports of 
trials and a description of one trial from ClinicalTrials.gov. Eleven trials were eligible for 
inclusion; 21 were excluded. Among the 11 trials eligible for inclusion, one trial is complete, 
but data analysis is underway (WACS); the other trial is not yet open for participant 
recruitment (NCT01142960). Nine and six trials were included in the qualitative and 
quantitative synthesis respectively.
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Included studies: Nine trials (117,272 individuals), ’The Antioxidants in Prevention of 
Cataracts Study’ (APC 2006), ’Age-Related Eye Disease Study’ (AREDS 2001), ’The 
Alpha-tocopherol Beta-carotene Study’ (ATBC 1998), ’Physician’s Health Study I’ (PHS I 
2003), ’Physician’s Health Study II’ (PHS II 2010), ’The Primary Prevention Project’ (PPP 
2001), ’The Roche European American Cataract Trial’ (REACT 2002), ’Vitamin E, Cataract 
and Age-related Maculopathy Trial’ (VECAT 2004) and ’Women’s Health Study’ (WHS 
2004/8) are included in this review.
The trials were conducted in Australia (VECAT 2004), Finland (ATBC 1998), India (APC 
2006), Italy (PPP 2001), the United Kingdom (REACT 2002) and the United States of 
America (AREDS 2001; REACT 2002; PHS I 2003; PHS II 2010; WHS 2004/8) from 1982 
to 2010. The duration of follow-up and treatment across these trials ranged from 2.1 to 12 
years.
Types of participants: The participants in the included trials were 35 years or older. In 
three trials (ATBC 1998; PHS I 2003; PHS II 2010) participants were exclusively male and 
in one trial (WHS 2004/8) exclusively female. More women than men comprised the study 
population of the other five trials (APC 2006; AREDS 2001; PPP 2001; REACT 2002; 
VECAT 2004). In two trials (REACT 2002; VECAT 2004) participants were required to 
have some degree of age-related cataract at enrollment and in one trial (ATBC 1998) only 
those who smoked more than five cigarettes a day were included. Those with a history of 
intraocular surgery were excluded from participation in APC 2006, those with a history of 
cataract surgery were not included in VECAT 2004 and those who were likely to have 
cataract extraction within two years of enrollment were excluded from REACT 2002. Those 
already taking vitamin supplements were not considered for inclusion in four trials (APC 
2006; ATBC 1998; REACT 2002; PHS I 2003; PHS II 2010).
Types of interventions: All included trials were controlled with placebo or alternate 
treatment; none of the trials had a ’no treatment’ control.
Three trials (ATBC 1998; PHS I 2003; WHS 2004/8) evaluated beta-carotene alone, one 
trial (PHS II 2010) evaluated vitamin C alone, five trials (ATBC 1998; PHS II 2010; PPP 
2001; VECAT 2004; WHS 2004/8) evaluated vitamin E alone, one trial (ATBC 1998) 
evaluated the combination of beta-carotene and vitamin E, one trial (PHS II 2010) evaluated 
the combination of vitamin C and vitamin E and three trials (APC 2006; AREDS 2001; 
REACT 2002) evaluated a combination of beta-carotene, vitamin C and vitamin E.
In all trials, the dose of antioxidant vitamins was higher than the RDA. The dose of beta-
carotene in PHS I 2003 (50 mg on alternate days) placed those on treatment in the top few 
percentiles of the general population with respect to usual intake. The dose of beta-carotene 
was similar in WHS 2004/8, 50 mg on alternate days. The dose of beta-carotene in ATBC 
1998 (20 mg once daily) was higher than the RDA and the dose of vitamin E (50 mg once 
daily) was more than five times the RDA. The doses of vitamin C (500 mg once daily) and 
vitamin E (400 IU every other day) in PHS II 2010 exceeded usual dietary levels. The dose 
of vitamin E (300 mg/day) in PPP 2001 is significantly higher than the RDA. The dose of 
vitamin E in VECAT 2004 (500 IU daily) was higher than the RDA. The dose of vitamin E 
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in WHS 2004/8 (600 IU every other day) was more than 13 times the RDA. The dose of the 
antioxidant vitamins (beta-carotene, vitamin C, vitamin E) were higher than the RDA in the 
three trials that evaluated the combination of these vitamins (APC 2006; AREDS 2001; 
REACT 2002). The dose in APC 2006 was beta-carotene, 15 mg; vitamin C, 500 mg; 
vitamin E, 400 IU three times a week. The dose in AREDS 2001 was beta-carotene, 15 mg; 
vitamin C, 500 mg; vitamin E, 400 IU daily. The dose in REACT 2002 was beta-carotene, 6 
mg; vitamin C, 250 mg; alpha-tocopherol 200 mg as a capsule three times daily.
Types of outcome measures
Primary outcomes
1. Incidence of cataract: Four trials (PHS I 2003; PHS II 2010; VECAT 2004; WHS 
2004/8) evaluated incidence of cataract.
In PHS I 2003 and PHS II 2010, cataract was defined as an incident, age-related lens opacity 
responsible for a reduction in best-corrected visual acuity (BCVA) to 20/30 or worse, with 
no alternate ocular disease to explain the visual acuity loss. The assessment of incidence was 
based on self report confirmed by medical record review. Data from the ’worse eye’ were 
analyzed. The results were presented as adjusted Cox proportional hazard ratios, with 95% 
confidence intervals (CI).
In VECAT 2004, the incidence of the three major types of age-related cataract was assessed 
separately. Lens opacities were assessed clinically using the Wilmer Lens Grading system 
and objectively using the NIDEK lens camera. A cataract was considered present clinically 
(Wilmer Lens Grading System), if the incident cortical or nuclear opacity was grade 2 or 
more, or if the posterior subcapsular opacity was 1 millimeter2(mm) or more. The change in 
grade had to be maintained for two consecutive years to be called an incident change. Data 
from the ’worse eye’ were analyzed. The results were presented as unadjusted risk ratios 
(with 95% CIs).
In WHS 2004/8, cataract was defined as a self report confirmed by medical record review to 
be initially diagnosed after randomization, age-related in origin, with BCVA of 20/30 or 
worse and no alternate ocular disease to explain the visual acuity loss. Data from the ’worse 
eye’ were analyzed. The results were presented as Cox proportional hazard ratios (with 95% 
CIs).
2. Incidence of cataract extraction: Eight trials (APC 2006; AREDS 2001; ATBC 1998; 
PHS I 2003; PHS II 2010; PPP 2001; VECAT 2004;WHS 2004/8) evaluated incidence of 
cataract extraction.
In APC 2006, cataract surgery was offered when BCVA decreased to 20/60 or worse or 
decreased visual acuity caused problems with everyday functioning. Data on BCVA 
assessment were unavailable to the authors of this review.
In AREDS 2001, events of cataract surgery were obtained from clinical reports. The results 
for cataract extraction were presented as both unadjusted relative risk and Cox proportional 
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hazard ratios, with 99% CIs adjusted for age, race, sex, baseline smoking status and age-
related macular degeneration.
In ATBC 1998, the incidence of cataract extraction was assessed separately for each of the 
interventions (beta-carotene alone, vitamin E alone and both). Cases were identified from 
the National Hospital Discharge Registry, which covered all hospitals performing cataract 
surgeries in Finland, using International Classification of Diseases codes. These codes do 
not differentiate the cataract types. The results were presented as incidence rate per 1000 
person-years, with 95% CI. The results also were presented as Cox proportional hazard 
ratios (with 95% CI) adjusted for baseline risk factors for cataract.
In PHS I 2003 and PHS II 2010, the assessment of incidence of cataract extraction was 
based on self report confirmed by medical record review. The results were presented as 
adjusted Cox proportional hazard ratios, with 95% CI.
In PPP 2001, the incidence of cataract surgery was collected at final visit (personal 
communication).
In VECAT 2004, data on type of cataract that led to the surgery were obtained from the 
operating surgeon. The results were presented as counts and percentages for vitamin E and 
placebo (with the P value from the Chi2 test).
In WHS 2004/8, the assessment of incidence of cataract extraction was based on self report 
confirmed by medical record review. The results were presented as Cox proportional hazard 
ratios, with 95%CIs adjusted for aspirin and vitamin E treatment assignment, stratified by 
categories of age.
Secondary outcomes
1. Progression of cataract: Four trials (APC 2006; AREDS 2001; REACT 2002; VECAT 
2004) evaluated progression of cataract.
In APC 2006, the progression of the three major types of age-related cataract was assessed 
separately. The primary outcome was change in nuclear opalescence from baseline as 
clinically evaluated by slit lamp using the Lens Opacities Classification System III (LOCS 
III) criteria. Secondary outcomes included change from baseline of nuclear color, cortical 
and posterior subcapsular opacities using the LOCS III criteria. The results were presented 
as difference in slope between the groups (with 95% CI) from generalized estimating 
equations.
In AREDS 2001, the three major types of age-related cataract were assessed separately. 
Progression was defined in terms of events; a cortical event was defined as a change from 
baseline of 10% of the area of a standard central 5 mm circle; a nuclear event was defined as 
a change in opacity from baseline of 1.5 U and a posterior subcapsular event was defined as 
a change from baseline of 5% of the area of a standard 5 mm circle. “Any lens event” 
included any of the above events or incident cataract surgery. “Severe lens event” included 
changes of 20% for cortical, 2.5 U (units/steps) for nuclear, 20%for posterior subcapsular 
cataracts. Slit lamp photographs were used to grade nuclear opacities and retroillumination 
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photographs were used to estimate the area of involvement for cortical and posterior 
subcapsular opacities. The results were presented as odds ratios (with 99% CI to account for 
multiple comparisons) from repeated measures logistic regression. For “any and severe lens 
event” both unadjusted and adjusted (for age, race, sex, baseline smoking status, age-related 
macular degeneration category) results were presented.
In REACT 2002, the primary outcome measure was increase in percent pixels opaque in the 
digital, anteriorly focused retroillumination image. Progression of cataract was defined as 
the difference between the last value and baseline value in percent pixels opaque. The three 
major types of age-related cataract were assessed separately using the LOCS III criteria: 
LOCS III C grade for cortical, LOCS III NO grade for nuclear and LOCS III P grade for 
posterior subcapsular cataract. The results were presented as mean of the last value, mean of 
change from baseline (with P values from analysis of variance) and as regression models 
from generalized estimating equations.
In VECAT 2004, the progression of the three major types of age-related cataract was 
assessed separately. Lens opacities were assessed clinically using the Wilmer Lens Grading 
system and objectively using masked grading of photos taken with the NIDEK lens camera. 
Progression was defined as (Wilmer Lens Grading System) an increase in cortical opacity by 
one grade or more, nuclear opacity by 0.5 of a grade or more and posterior subcapsular 
opacity by 1 mm2 or more. As stated earlier, the change in grade had to be maintained for 
two consecutive years to be considered as progression. The results were presented as 
unadjusted risk ratios (with 95% CI).
2. Loss of visual acuity: Three trials (APC 2006; AREDS 2001; REACT 2002) evaluated 
loss of visual acuity.
In APC 2006, visual acuity was evaluated using the National Eye Institute Early Treatment 
Diabetic Retinopathy Study (ETDRS) logMAR (logarithm of minimum angle of resolution) 
chart using standard methodology. The results were presented as change in BCVA from 
baseline (with standard deviation) at the end of the study.
In AREDS 2001, loss of visual acuity was defined as decrease in BCVA score from baseline 
of 15 or more letters which is equivalent to doubling of more of the initial visual angle. 
Visual acuity was measured every six months and was measured according to the ETDRS 
protocol. The results were presented as unadjusted and adjusted odds ratios (adjusted for 
age, race, sex, baseline smoking status), with 99% CIs from repeated measures logistic 
regression.
In REACT 2002, visual acuity was presented as mean of the last value and mean of change 
from baseline (with P values from analysis of variance) on the logMAR scale. Visual acuity 
was assessed approximately every four months.
Excluded studies: We excluded 21 trials after full-text review. Among these, two 
trials, ’The Linxian Cataract Study’ (LINXIAN 1993) and ’Lutein, but not alpha-tocopherol 
supplementation improves visual function in patients with age-related cataracts: a 2 year 
double blind, placebo controlled pilot study’ (Olmedilla 2003) were excluded after detailed 
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methodological review. The trial ’The role of antioxidants in the prevention of cancer and 
cardiovascular disease’ (SUVIMAX 1998) was excluded after the principal investigator 
reported that ’eye’ outcomes were not examined.
Risk of bias in included studies: Figure 2 and Figure 3 present a summary of the risk of 
bias for the included studies.
Allocation
Random sequence generation—We judged random sequence generation as unclear 
risk of bias for ATBC 1998 because it was not described in the published report. We judged 
random sequence generation to be at low risk of bias for the remaining eight studies 
included in this review. In APC 2006 randomization was performed in blocks of 40. In 
REACT 2002 Efron’s biased coin method was used and in VECAT 2004 randomization was 
performed using permuted blocks. In AREDS 2001 the investigators used simple 
randomization stratified by clinical center and presence of age-related macular degeneration. 
Assignments were stored in two treatment assignment databases housed at the Co-ordinating 
Center. In PHS I 2003; PHS II 2010; PPP 2001; WHS 2004/8 randomization was performed 
using a computer-generated list of random numbers.
Method of allocation concealment—ATBC 1998 investigators did not describe the 
method of allocation concealment so we judged it as unclear risk of bias.
We judged the method of allocation concealment at low risk of bias for the remaining eight 
studies included in this review. In APC 2006, the placebo tablets were identical to active 
tablets in appearance and taste. In AREDS 2001, multiple unique bottle codes were 
randomly assigned to each treatment category; a bottle code corresponding to the assigned 
treatment was randomly selected for each participant. The AREDS study tablets were 
identical in external and internal appearance and taste. The co-ordinating center was the 
custodian of the treatment code. In PPP 2001, treatments were centrally assigned on 
telephone verification of the correctness of inclusion criteria with a separate computer-
generated randomization table produced for each physician in random permuted blocks of 
12. In REACT 2002, the individuals who prepared the randomization scheme were not 
involved in determining eligibility, administering the intervention or assessing the outcome. 
The task of generating the random assignment and the task of executing the assignment 
(consulting the assignment system for the participants intervention designation after 
determining eligibility) were performed by different individuals. The intervention 
assignment was not known to center administrators until the study was closed. It is unclear 
whether the study tablets were identical in external and internal appearance and taste. In 
VECAT 2004, the allocation list was stored at a remote site and the medications were 
dispensed in identical containers. All study information was obtained, collated and 
interpreted before the randomized assignment was broken. In PHS I 2003; PHS II 2010 and 
WHS 2004/8 the study pills in the treatment arms were identical except for the active agent 
in the beta-carotene group (personal communication).
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Blinding—We judged PPP 2001 at high risk of bias with regards to masking of care 
providers and participants. It is unclear whether the validation of clinical end points by an 
expert committee that was masked to the treatment assignment extended to the outcome of 
interest in this review (incidence of cataract extraction). Hence, overall we judged it to be at 
unclear risk of bias.
We judged masking at low risk of bias for the remainder of the eight studies included in this 
review. The care providers, participants and outcome assessors were masked in all these 
studies.
Incomplete outcome data
Losses to follow-up—In REACT 2002, 22% (n = 66) were lost after two years and 47% 
(n = 139) after three years. The authors report that the losses were equivalent between the 
intervention groups. We judged it as a high risk of bias.
In APC 2006, losses to follow-up were not reported in the published report. However, the 
losses to follow-up were equal across treatment groups (personal communication). In ATBC 
1998, 28.4% in the alpha-tocopherol group and 29.4% in the beta-carotene group were lost 
by the end of the trial. In VECAT 2004, 25.6% (n = 152) in the treatment group and 23.8% 
(n = 142) in the placebo group were lost by the end of the trial. We judged these as unclear 
risk of bias.
We judged the remaining five studies at low risk of bias. In AREDS 2001, 0.7% (n = 33) of 
participants did not have at least one follow-up, however, 90% had at least five years of 
follow-up. Fourteen per cent withdrew from study medication after five years and 15% by 
the end of the trial (this includes those lost to follow-up and current smokers who withdrew 
from the study after the results of clinical trials of beta-carotene and lung cancer were 
announced).
In PHS I 2003, 99.2% provided information on morbidity for 11 years into the study. In PHS 
II 2010, morbidity and mortality follow-up rates were 95.3% and 97.7% respectively. In PPP 
2001, losses to follow-up were 0.6% and 0.75% in the treatment and placebo arms 
respectively. In WHS 2004/8, morbidity and mortality follow-up rates at the termination of 
the beta-carotene arm (median 2.1 years) were 99% (personal communication) and for the 
vitamin E component 97.2% and 99.4% respectively.
Selective reporting—We did not identify any selective reporting across the nine trials 
that are included in this review. The results were reported for outcomes as described in the 
methods section in these trials. However, we did not have access to the study protocol for 
the nine trials.
Other potential sources of bias
Intention-to-treat analysis—We considered the analysis to be intention-to-treat as long 
as trial participants were analyzed in the groups to which they were randomized irrespective 
of which or how much treatment they actually received.
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Analysis was based on intention-to-treat for all nine trials included in this review.
In APC 2006; ATBC 1998; PHS I 2003; PHS II 2010; PPP 2001 and WHS 2004/8, data 
were analyzed according to the intention-to-treat principle, regardless of actual compliance.
In AREDS 2001, the authors report that the original treatment group assignments were 
retained for the analysis. Thirty-three (0.7%) participants who did not have at least one 
follow-up were excluded from the analysis for “any lens event” and “incidence of cataract 
extraction” (’available case’ analysis). The outcome ’visual acuity’ was assessed in 1117 
people without age-related macular degeneration at baseline. In REACT 2002, the authors 
report that the analysis was conducted on an intention-to-treat basis. The primary analysis 
was performed on completers at three years. Forty-seven per cent (n = 139) of those 
randomized were lost during this period. Additional analysis on “all randomized” was also 
performed. In VECAT 2004, the authors reported performing an “on protocol” (continuing 
study medication) and “off protocol” (cessation of study medication but continuing 
participation in the examinations) analysis in addition to intention-to-treat analysis. For 
incidence of any cataract, the first development of any of the three types of cataract was 
included in the numerator, but the cases in which any cataract was present at baseline were 
excluded. The denominator included all the cases of known outcome that were free of 
cataract at baseline. For progression, the numerator included cases of measured progression 
and the denominator included only those cases where assessment of progression was 
feasible.
Exclusions post randomization—In PHS II 2010, exclusions post randomization were 
high, 3096 or 21% of those randomized were excluded post randomization because of the 
presence of cataract at baseline. These were similar across treatment groups.
Exclusions post randomization were low to none in the remaining eight studies included in 
this review. In APC 2006, there were no exclusions after randomization (personal 
communication). In AREDS 2001, those with bilateral aphakia or pseudophakia (n = 128, 
2.7% of randomized) were participants for only the age-related macular degeneration part of 
the study and were excluded from the cataract trial. In ATBC 1998, those who had cataract 
extraction before enrolment (n = 199, 0.7% of randomized) were excluded from the analysis. 
In PHS I 2003, those with cataract at baseline (n = 1103, 5% of those randomized) were 
excluded from the analysis. The proportion of those excluded post randomization were 
equivalent across the two study groups. In PPP 2001, there were no exclusions post 
randomization. In REACT 2002, there were no exclusions post randomization; however 
only ’completers’ at the end of the study were analyzed. In VECAT 2004, those not 
satisfying the age criteria (n = 11, 0.9% of randomized) were excluded. In WHS 2004/8 
those who reported history of cataract at baseline (n = 3141, 7.9%, n = 2201, 5.5% of 
randomized; for beta-carotene and vitamin E arms respectively) were excluded from the 
analysis. The proportions excluded were equivalent across the study groups.
Equivalence of baseline characteristics—In REACT 2002, participants from the 
United Kingdom were slightly older, had lower serum proteins, poorer liver function, lower 
vitamin levels, less brunescent lenses (opacity of the lens that is brownish in color) and more 
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nuclear and cortical opacification. In the Australian study, VECAT 2004, the vitamin E arm 
had a greater number of cases of cortical and any cataract at baseline. We judged these 
studies to have an unclear risk of bias.
Important characteristics were equally distributed across the treatment groups in the 
remaining seven trials included in this review.
Adherence to treatment—Adherence to treatment was high for all nine trials included in 
this review.
In APC 2006, a field worker witnessed administration of active and identical appearing 
placebo tablets three times weekly. In AREDS 2001, adherence, defined as consumption of 
more than 75% of their study tablets, was estimated to be more than 75% for 70% of 
participants at five years. In ATBC 1998, 80% of active participants (those coming for 
follow-up visits) were taking more than 95% of their capsules at each of the follow-up visits. 
In PHS I 2003, even after 11 years in the study, 78% of the study pills were still reported as 
being taken. In PHS II 2010, compliance, defined as taking more than two-thirds of the 
study agents, was greater than 70% at the end of follow-up. In PPP 2001, 13.1% and 13.6% 
of those randomized to vitamin E were not taking the medication at year one and at the end 
of the study. In REACT 2002, compliance as assessed by plasma concentrations of 
antioxidant vitamins appears to be high. In VECAT 2004, 77% of actively treated and 79% 
of those in the placebo group were estimated to have consumed 80% or more of their 
capsules. In WHS 2004/8, 87% of the beta-carotene arm reported taking at least two-thirds 
of study capsules, and 78.9% and 71.6% of vitamin E part of the trial were taking at least 
two-thirds of study capsules at five years and 10 years respectively.
The plasma concentrations of antioxidant vitamins were assessed in four studies (AREDS 
2001; REACT 2002; VECAT 2004; WHS 2004/8). The result showed an increase in levels 
of the corresponding antioxidant vitamins assessed during follow-up.
Effects of interventions
Primary outcomes
1. Incidence of cataract—Four trials (PHS I 2003; PHS II 2010;VECAT 2004; WHS 
2004/8) evaluated the incidence of cataract. We pooled the results for beta-carotene and 
vitamin E.
Beta-carotene versus placebo: Two trials (PHS I 2003; WHS 2004/8) compared beta-
carotene with placebo. In PHS I 2003, which evaluated 22,071 male physicians between 40 
and 84 years in the United States, there was no difference between beta-carotene (50 mg on 
alternate days) and placebo in the risk of incidence of cataract over 12 years of follow-up. 
The Cox proportional hazard ratio adjusted for aspirin assignment was 1.0 (95% confidence 
interval (CI) 0.91 to 1.09). In WHS 2004/8, which evaluated 39,876 female health 
professionals of age 45 years or older in the United States, there was no difference between 
beta-carotene (50 mg on alternate days) and placebo in the risk of incidence of cataract over 
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a median period of 2.1 years. The Cox proportional hazard ratio adjusted for aspirin and 
vitamin E assignment was 0.95 (95% CI 0.75 to 1.21).
In the pooled analysis of these two trials (PHS I 2003; WHS 2004/8) involving 57,703 
participants, there was no evidence of effect of beta-carotene supplementation in reducing 
the risk of incidence of cataract. The summary relative risk (RR) was 0.99 (95% CI 0.91 to 
1.08). The test for heterogeneity was not statistically significant (Chi2 = 0.15, P = 0.69; I2 = 
0%) (Analysis 1.1).
Vitamin C versus placebo: Only one trial (PHS II 2010) compared vitamin C with placebo. 
In this trial which evaluated 14,641 male physicians of age 50 years or older, there was no 
difference between vitamin C (500 mg daily) and placebo in the risk of incidence of cataract 
over a mean period of eight years of follow-up. The adjusted Cox proportional hazard ratio 
was 1.02 (95% CI 0.91 to 1.14). There were no differences in risk by types of cataract 
(Analysis 2.1).
Vitamin E versus placebo: Three trials (PHS II 2010; VECAT 2004; WHS 2004/8) 
compared vitamin E with placebo. In PHS II 2010, there was no difference between vitamin 
E (400 IU daily) and placebo in the risk of incidence of cataract over a mean period of eight 
years of follow-up. The adjusted Cox proportional hazard ratio was 0.99 (95% CI 0.88 to 
1.11). In VECAT 2004, which evaluated 1204 volunteers between 55 and 80 years in 
Australia, there was no difference between vitamin E (500 IU daily) and placebo in the risk 
of incidence of any cataract over four years of follow-up. The risk ratio was 1.0 (95% CI 0.8 
to 1.4). In WHS 2004/8, there was no difference between vitamin E (600 IU on alternate 
days) and placebo in the risk of incidence of any cataract over an average of 9.7 years of 
follow-up. The Cox proportional hazard ratio adjusted for aspirin and beta-carotene 
assignments was 0.96 (95% CI 0.88 to 1.04). There were no differences in risk by types of 
cataract.
In the pooled analysis of three trials (PHS II 2010; VECAT 2004; WHS 2004/8) involving 
50,059 participants, there was no evidence of effect of vitamin E supplementation in 
reducing the risk of incidence of cataract. The summary RR was 0.97 (95%CI 0.91 to 1.04). 
The test for heterogeneity was not statistically significant (Chi2 = 0.22, P = 0.90; I2 = 0%). 
Similarly, in the subgroup analysis, there was no difference in effect by type of cataract. The 
RRs (95% CIs) were 0.94 (0.84 to 1.04), 0.96 (0.90 to 1.03), 0.97 (0.86 to 1.09) for cortical, 
nuclear and posterior subcapsular cataract respectively (Analysis 3.1).
Vitamin C and vitamin E versus placebo: Only one trial (PHS II 2010) compared the 
combination of vitamin C and vitamin E with placebo. In this trial, there was no difference 
between the combination of vitamin C (500 mg daily) and vitamin E (400 mg IU on 
alternate days) with placebo in the risk of incidence of cataract over a mean period of eight 
years of follow-up. The Mantel-Haenszel risk ratio was 0.98 (95%CI 0.84 to 1.15). There 
were no differences in risk by types of cataract (Analysis 5.1).
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2. Incidence of cataract extraction—Eight trials (APC 2006; AREDS 2001; ATBC 
1998; PHS I 2003; PHS II 2010; PPP 2001; VECAT 2004; WHS 2004/8) reported incidence 
of cataract extraction. We pooled the results for beta-carotene and vitamin E.
Beta-carotene versus placebo: Three trials (ATBC 1998; PHS I 2003; WHS 2004/8) 
compared beta-carotene with placebo. In ATBC 1998, which evaluated 29,133 male 
smokers between 50 and 69 years in Finland, there was no difference between beta-carotene 
(20 mg per day) and placebo in the risk of incidence of cataract extraction over a median 
period of 5.7 years of follow-up. The Cox proportional hazard ratio adjusted for risk factors 
for cataract was 0.97 (95% CI 0.79 to 1.19). In PHS I 2003, there was no difference between 
the beta-carotene and placebo groups in the risk of incidence of cataract extraction over 12 
years of follow-up. The Cox proportional hazard ratio adjusted for aspirin assignment was 
1.00 (95% CI 0.89 to 1.12). In WHS 2004/8, there was no difference between the beta-
carotene and placebo groups in the risk of incidence of cataract extraction over a median 
period of 2.1 years. The Cox proportional hazard ratio adjusted for aspirin and vitamin E 
assignment was 1.04 (95% CI 0.78 to 1.39).
In the pooled analysis of three trials (ATBC 1998; PHS I 2003; WHS 2004/8) involving 
86,836 participants there was no evidence of effect of beta-carotene supplementation in 
reducing the risk of cataract extraction. The summary RR was 1.0 (95% CI 0.91 to 1.10). 
The test for heterogeneity was not statistically significant (Chi2 = 0.15, P = 0.93; I2 = 0%) 
(Analysis 1.2).
Vitamin C versus placebo: Only one trial (PHS II 2010), compared vitamin C with 
placebo. In this trial, there was no difference between vitamin C and placebo in the risk of 
incidence of cataract over a mean period of eight years of follow-up. The adjusted Cox 
proportional hazard ratio was 0.97 (95% CI 0.85 to 1.12). There were no differences in risk 
by types of cataract (Analysis 2.2).
Vitamin E versus placebo: Five trials (ATBC 1998; PHS II 2010; PPP 2001; VECAT 
2004; WHS 2004/8) compared vitamin E with placebo. In ATBC 1998, there was no 
difference between vitamin E (50 mg once daily) and placebo in the incidence of cataract 
extraction over a median period of 5.7 years of follow-up. The Cox proportional hazard ratio 
adjusted for risk factors for cataract was 0.91 (95% CI 0.74 to 1.11). In PHS II 2010, there 
was no difference between vitamin E and placebo in the risk of incidence of cataract 
extraction over a mean period of eight years of follow-up. The adjusted Cox proportional 
hazard ratio was 0.96 (95% CI 0.83 to 1.10). There were no differences in risk by types of 
cataract. In PPP 2001, which evaluated 4495 volunteers of age 50 years or older in Italy, 
there was no difference between vitamin E (300 mg daily) and placebo in the risk of 
incidence of cataract extraction over a mean period of 3.6 years of follow-up. The 
unadjusted risk ratio was 1.03 (95% CI 0.73 to 1.46) (personal communication). In VECAT 
2004, there was no difference between vitamin E and placebo in the risk of incidence of 
cataract extraction over four years of follow-up. The RR was 1.09 (95% CI 0.69 to 1.72). In 
WHS 2004/8, there was no difference between vitamin E and placebo in the risk of 
incidence of cataract extraction over an average of 9.7 years of follow-up. The Cox 
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proportional hazard ratio adjusted for aspirin and beta-carotene assignments was 1.00 (95% 
CI 0.91 to 1.11). There were no differences in risk by types of cataract.
Pooled analysis: In the pooled analysis of these five trials (ATBC 1998; PHS II 2010; PPP 
2001; VECAT 2004;WHS 2004/8) involving 83,956 participants, there was no evidence of 
effect of vitamin E supplementation in reducing the risk of cataract extraction. The pooled 
RR is 0.98 (95% CI 0.91 to 1.05). The test for heterogeneity was not statistically significant 
(Chi2 = 1.04, P = 0.90; I2 = 0%). Similarly, in the subgroup analysis involving two trials 
(PHS II 2010; WHS 2004/8) there was no difference in effect by type of cataract. The RRs 
(95% CI) were 0.92 (0.81 to 1.05), 0.99 (0.91 to 1.07), 1.02 (0.89 to 1.16) for cortical, 
nuclear and posterior subcapsular cataract respectively (Analysis 3.2).
Beta-carotene plus vitamin E versus placebo: Only one trial (ATBC 1998) compared the 
combination of beta-carotene and vitamin E with placebo. In this trial, there was no 
difference between combined supplementation (beta-carotene with vitamin E) and placebo 
in the risk of incidence of cataract extraction over a median period of 5.7 years. The rate 
ratio for incidence of cataract extraction was 0.92 (95% CI 0.70 to 1.21) (Analysis 4.1).
Beta-carotene plus vitamin C plus vitamin E versus placebo: Two trials (APC 2006; 
AREDS 2001) compared the combination of beta-carotene, vitamin C and vitamin E with 
placebo. Data from APC 2006 are unavailable. In AREDS 2001, which evaluated 4757 
volunteers between 55 and 80 years in the United States, there was no difference between 
antioxidant and no antioxidant for the risk of cataract surgery over a mean period of 6.3 
years. The Cox proportional hazard ratio adjusted for age, race, sex and smoking status was 
0.97 (95% CI 0.83 to 1.13) (Analysis 6.1).
Secondary outcomes
1. Progression of cataract—Four trials (APC 2006; AREDS 2001; REACT 2002; 
VECAT 2004) evaluated progression of cataract. We did not pool results because of 
differences in the definitions of the outcomes and differences in the analysis and 
presentation of data. Data from the primary studies are presented in ’Other data tables’.
No trials compared either beta-carotene or vitamin C with placebo.
Vitamin E versus placebo: Only one trial (VECAT 2004) compared vitamin E with 
placebo. In this trial, there was no difference between the vitamin E and placebo groups in 
the risk of progression of any cataract over four years of follow-up. The risk ratio was 1.0 
(95% CI 0.7 to 1.3). There was no difference in risk by types of cataract (Analysis 3.3).
Beta-carotene plus vitamin C plus vitamin E versus placebo: Three trials (APC 2006; 
AREDS 2001; REACT 2002) compared the combination of beta-carotene, vitamin C and 
vitamin E with placebo. In APC 2006, which evaluated 798 volunteers between 35 and 50 
years in India, there was no difference between antioxidant (beta-carotene: 15 mg, vitamin 
C: 500 mg, vitamin E: 400 IU, three times a week) and placebo in the risk of progression of 
cataract over five years. The results were similar by type of cataract and by age groups. In 
AREDS 2001, there was no difference between antioxidant (beta-carotene: 15 mg, vitamin 
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C: 500 mg, vitamin E: 400 IU daily) and no antioxidant for the risk of any lens event 
(includes cataract surgery) over a mean period of 6.3 years. The odds ratio (OR) adjusted for 
age, race, gender, baseline smoking status and age-related macular degeneration category 
was 1.0 (95%CI 0.90 to 1.11). The results were similar for the risk of a severe lens event, 
OR 0.95 (95%CI 0.82 to 1.10). There was also no difference in the risk by type of cataract. 
In REACT 2002, which evaluated 297 participants over 40 years in the United States and 
the United Kingdom, the generalized estimating equations with last values carried forward 
to account for dropouts, the increase in percent pixels opaque of placebo group compared to 
antioxidant group was 0.509. However this difference, though in favor of antioxidants, was 
not statistically significant. The authors report finding a beneficial effect in the subgroups of 
those with no or early cataract irrespective of length of follow-up, and in those with 
moderate to more advanced cataracts in both the United States and the United Kingdom. 
However in this study 22% (n = 66) were lost after two years and 47% (n = 139) after three 
years of follow-up. In the ANOVA analysis of participants completing the study at three 
years, progression of cataract as defined by mean (95% CI) increase in percent pixels 
opaque was 1.661 (+/− 0.984) in the antioxidant group as compared to 3.273 (+/− 1.406) in 
the placebo group, P = 0.048. The results were not statistically significant by type of cataract 
(assessed as increase in LOCS III C grade) (Analysis 6.2).
2. Loss of visual acuity—Three studies (APC 2006; AREDS 2001;REACT 2002) 
evaluated loss of visual acuity. All three studies examined a combination of beta-carotene, 
vitamin C and vitamin E with placebo.
Beta-carotene plus vitamin C plus vitamin E versus placebo: In APC 2006, there was no 
difference between antioxidant and placebo for change in visual acuity. The BCVA of the 
antioxidant group was a mean of 1.64 letters less (standard deviation (SD) 4.74) at year five 
compared to baseline while that of the placebo group was a mean of 1.66 letters less (SD 
4.96). In AREDS 2001, there was no difference between antioxidant and placebo for the risk 
of loss of 15 or more letters in visual acuity score compared with baseline measurement over 
a mean period of 6.3 years. The OR from repeated measures logistic regression adjusted for 
age, race, sex and smoking status was 1.07 (95% CI 0.74 to 1.54). In REACT 2002, there 
was no difference between antioxidant and placebo in logMAR visual acuity among 
completers over a period of three years. The mean change (95% CI) in the antioxidant group 
was −0.052 (+/− 0.027) as compared to −0.073 (+/− 0.034) in the placebo group, P = 0.189 
(Analysis 6.3).
Adverse effects: See additional Table 1 ’Adverse events: hypercarotenodermia’.
The proportion of participants developing hypercarotenodermia (yellowing of skin) while on 
beta-carotene was 8.6% (n = 203) in AREDS 2001, 8.8% (n = 1281) in ATBC 1998, 15.8% 
(n = 1745) in PHS I 2003 (data from PHS 1996), 7.4% (n = 6) in REACT 2002 and 10.7% 
(n = 2131) in WHS 2004/8 (data from WHS 1999).
In VECAT 2004, there was no statistically significant difference between the vitamin E and 
placebo groups on number and type of adverse events according to the body system 
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involved. In WHS 2004/8, those on vitamin E had a statistically significant increase in risk 
of epistaxis (bleeding from the nose) (RR 1.06, 95% CI 1.01 to 1.11).
DISCUSSION
Summary of main results
This review contains important findings regarding the failure of antioxidant vitamin 
supplementation to prevent and slow incidence and progression of age-related cataract.
The four trials that examined incidence of cataract did not find any evidence of effect for 
beta-carotene (PHS I 2003; WHS 2004/8) vitamin C (PHS II 2010), vitamin E (PHS II 2010; 
VECAT 2004; WHS 2004/8) or vitamin C and vitamin E in combination (PHS II 2010). 
Additionally, there was no evidence of effect of antioxidant supplementation by type of 
cataract with vitamin C and vitamin E supplementation either as single agents or in 
combination (PHS II 2010). Furthermore, our fixed-effect meta-analysis did not show any 
evidence of effect for beta-carotene or vitamin E on incidence of cataract.
The eight trials that examined incidence of cataract extraction did not find any evidence of 
effect for beta-carotene (ATBC 1998; PHS I 2003;WHS 2004/8), vitamin C (PHS II 2010), 
vitamin E (ATBC 1998; PHS II 2010; PPP 2001;VECAT 2004;WHS 2004/8) or beta-
carotene and vitamin E in combination (ATBC 1998), or all of the three in combination 
(AREDS 2001). Additionally, there was no evidence of effect by type of cataract with 
vitamin C (PHS II 2010) or vitamin E supplementation (PHS II 2010; VECAT 2004; WHS 
2004/8). Our fixed-effect meta-analysis did not show any evidence of effect for either beta-
carotene or vitamin E on incidence of cataract extraction.
The four trials that examined progression of cataract, regardless of designation of type, did 
not find any evidence of effect for either vitamin E alone (VECAT 2004) or all three 
antioxidants in combination (APC 2006; AREDS 2001; REACT 2002). Progression of 
cataract was defined differently in these four trials. In REACT 2002, though the effect 
estimate for progression of cataract (as the primary outcome) favored antioxidant 
supplementation as reported by the authors, their finding should be interpreted with caution 
because of the high attrition rate in the trial. Moreover, the test of statistical significance for 
this outcome yielded a probability considered “borderline.” None of the effect estimates for 
progression of cataract (as secondary outcomes) were statistically significant. Additionally, 
the results by type of cataract were not statistically significant. In VECAT 2004, the non-
statistically significant increase in progression of cataract (RR 2.5, 95% CI 0.6 to 11.2) and 
the non-significant decrease in incidence of cataract (RR 0.5, 95% CI 0.2 to 1.1) in the 
subgroup of posterior subcapsular cataract should be interpreted with caution because of the 
low event rates and very small sample size.
The three studies that examined loss of visual acuity did not find any evidence of a 
beneficial effect for all the three antioxidants in combination (APC 2006; AREDS 2001; 
REACT 2002).
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Overall completeness and applicability of evidence
A large number of trials have examined the role of antioxidant vitamins in relation to age-
related cataract. However, only 10 of these were randomized controlled trials with a follow-
up of at least one year. Nine trials (117,272 individuals) with follow-up ranging from 2.1 to 
12 years are included in this review. One trial (WACS) has been completed and data 
analysis is underway. The included trials were conducted in Australia (VECAT 2004), 
Finland (ATBC 1998), India (APC 2006), Italy (PPP 2001), the United Kingdom (REACT 
2002) and the United States of America (AREDS 2001; REACT 2002; PHS I 2003; PHS II 
2010; WHS 2004/8) from 1982 to 2010.
The population in these trials were 35 years or older and three (ATBC 1998; PHS I 2003; 
PHS II 2010) of these were conducted on men only. One trial (WHS 2004/8) was conducted 
exclusively on women. Two trials (REACT 2002; VECAT 2004) were secondary prevention 
trials in which participants were required to have some degree of age-related cataract at 
baseline. Three trials (ATBC 1998; PHS I 2003; WHS 2004/8) examined beta-carotene as a 
single agent, one trial examined vitamin C as a single agent (PHS II 2010) and five trials 
(ATBC 1998; PHS II 2010; PPP 2001; VECAT 2004; WHS 2004/8) examined vitamin E as 
a single agent. One trial (ATBC 1998) evaluated a combination of beta-carotene and vitamin 
E, another trial (PHS II 2010) evaluated a combination of vitamin C and vitamin E and three 
trials (APC 2006; AREDS 2001; REACT 2002) evaluated the combination of all these three 
antioxidant vitamins. Four trials (PHS I 2003; PHS II 2010; VECAT 2004; WHS 2004/8) 
evaluated the incidence of cataract. Eight trials (APC 2006; AREDS 2001; ATBC 1998; 
PHS I 2003; PHS II 2010; PPP 2001; VECAT 2004; WHS 2004/8) evaluated incidence of 
cataract extraction. Four trials (APC 2006; AREDS 2001; REACT 2002; VECAT 2004) 
evaluated progression of cataract and three studies (APC 2006; AREDS 2001; REACT 
2002) evaluated loss of visual acuity. The doses of antioxidant supplementation were higher 
than the RDA in all trials.
This systematic review of world literature suggests that there is no evidence of effect of the 
antioxidant vitamins beta-carotene, vitamin C and vitamin E on the incidence of cataract, 
incidence of cataract extraction, progression of cataract or loss of visual acuity. Several 
characteristics of the populations of these studies are noteworthy. Firstly, these studies 
included only those aged 35 years or older. It is possible that supplementation should be 
started at an earlier age to demonstrate a beneficial effect. Secondly, the protective effect of 
antioxidant vitamins perhaps may take decades of intake to manifest. Thirdly, all the 
included studies except APC 2006 were done in the developed world on apparently healthy 
individuals. The nutritional status of these individuals could be quite different from those in 
the developing world. Lastly, there are many different types of antioxidants, some natural 
and some synthetic, and the conclusions drawn here should be limited to supplementation 
with beta-carotene, vitamin C and vitamin E only. It is possible that there are other 
antioxidants that are beneficial in relation to age-related cataract.
Though this systematic review did not find any protective effect for antioxidant vitamin 
supplementation, its results should not be extrapolated to imply that consumption of fruits 
and vegetables which are rich in antioxidant vitamins and other substances is not beneficial. 
The included studies used supplements in doses that were higher than the RDA for these 
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antioxidant vitamins. It is possible that these doses are toxic. Fruits and vegetables contain 
safe amounts of antioxidants; only high levels of antioxidants that result from 
supplementation could be detrimental.
It has been suggested that beta-carotene may be a co-carcinogen (Paolini 2003). In this 
review, hypercarotenodermia (yellowing of skin) was observed in 7% or more of those 
taking beta-carotene among the participants of AREDS 2001, ATBC 1998, PHS I 2003, 
REACT 2002 and WHS 2004/8. There was a statistically significant 6% increase in 
epistaxis among those taking vitamin E in participants of WHS 2004/8. Additionally, studies 
have shown that beta-carotene used as a single agent or in combination with vitamin A and 
vitamin E either had no effect or a statistically significant increase in mortality (Bjelakovic 
2004; Caraballoso 2003; Vivekananthan 2003). In the light of no evidence of effect for beta-
carotene, vitamin C and vitamin E supplementation with respect to cataract and visual acuity 
and with evidence of adverse effects for beta-carotene and vitamin E, recommendations for 
use should be made with a great degree of caution. It should be noted that as with beneficial 
effects, adverse effects for these antioxidant vitamins and adverse effects of other 
antioxidants may require decades of intake to manifest.
The use of antioxidant vitamin supplementation by the general population of western 
countries is probably high. According to data from the Women’s Health Initiative more than 
half the women were taking antioxidants in some form (WHI 2003). In view of the lack of 
evidence of a protective effect of antioxidant vitamin supplementation and the increase in 
risk associated with its use, great efforts should be made to educate physicians and the 
public about their potential deleterious effects. The ease of availability of these antioxidant 
vitamins over the counter and aggressive marketing strategies make awareness of these 
issues a pressing public health necessity.
Quality of the evidence
We have been able to demonstrate, with high-quality evidence, the failure of antioxidant 
vitamin supplementation in preventing and slowing the progression of age-related cataract.
Only one trial (REACT 2002) was judged to be at ’high risk of bias’ (for incomplete 
outcome data) with respect to the parameters of quality assessed in this review. However, 
this trial did not demonstrate any convincing evidence of effect and was not included in any 
meta-analysis.
Among the trials that were pooled, three (ATBC 1998; PPP 2001; VECAT 2004) were 
judged at ’unclear risk of bias’ for select parameters of quality. It is possible for selection 
bias to have influenced the results of ATBC 1998. The care providers and participants were 
not masked in PPP 2001, and the losses to follow-up were high in ATBC 1998 and VECAT 
2004. However, these trials did not demonstrate any evidence of effect and their contribution 
(weight) towards the pooled estimates were low. The weights were: ATBC 1998 12.9% and 
21.4%, PPP 2001 4.4% and VECAT 2004 2% to 5.5%. The remainder of the trials that were 
pooled (PHS I 2003; PHS II 2010; WHS 2004/8) were of high methodological quality.
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Potential biases in the review process
We are unable to identify any significant biases in the review process.
We conducted a comprehensive search that included searching major databases, reference 
lists of published trials and contacting experts in this field for information on trials. To our 
knowledge, there are no other trials that have examined the antioxidant vitamins beta-
carotene, vitamin C and vitamin E in relation to age-related cataract that would have met the 
inclusion criteria. Data extraction was conducted in duplicate by two review authors; data 
entry and related analyses were entered by one author and verified by a second.
Agreements and disagreements with other studies or reviews
The results of the individual trials and the pooled analysis are similar. They failed to 
demonstrate any evidence of effect of antioxidant supplementation in preventing the 
formation and slowing the progression of age-related cataract. Additionally, this review 




There is no evidence from randomized controlled trials that antioxidant vitamin 
supplementation with beta-carotene, vitamin C and vitamin E prevents or slows the 
progression of age-related cataract. Costs and adverse effects should be weighed carefully 
with unproven benefits before recommending their use.
Implications for research
We do not recommend any further studies to examine the role of antioxidant vitamins beta-
carotene, vitamin C and vitamin E in preventing or slowing the progression of age-related 
cataract.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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#1 MeSH descriptor beta Carotene
#2 beta carotene*
#3 MeSH descriptor Ascorbic Acid
#4 ascorbic acid*
#5 vitamin C
#6 MeSH descriptor Vitamin E




#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR (#7 AND #8) OR #9 OR #10)
#12 MeSH descriptor Cataract
#13 cataract*
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#14 (#12 OR #13)
#15 (#11 AND #14)
Appendix 2
MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. exp beta carotene/
14. caroten$.tw.
15. exp ascorbic acid/
16. ascorbic acid$.tw.
17. vitamin C.tw.








26. 22 and 25
27. 12 and 26
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The search filter for trials at the beginning of the MEDLINE strategy is from the published 
paper by Glanville et al (Glanville 2006).
Appendix 3
EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1–5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12–21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
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28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25–28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
Appendix 4
LILACS search strategy
beta carotene or vitamin C or vitamin E and cataract$
Appendix 5
OpenGrey search strategy
(beta carotene OR vitamin C OR vitamin E) AND cataract
Appendix 6
metaRegister of Controlled Trials search strategy
(vitamin c or vitamin e or beta carotene) and cataracts
Appendix 7
ClinicalTrials.gov search strategy
(Vitamin C or Vitamin E or beta carotene) AND Cataract
Appendix 8
ICTRP search strategy
cataract = condition AND vitamin or beta carotene = intervention
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Results from searching for studies for inclusion in the review.
Mathew et al. Page 35














’Risk of bias’ summary: review authors’ judgments about each risk of bias item for each 
included study.
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’Risk of bias’ graph: review authors’ judgments about each risk of bias item presented as 
percentages across all included studies.
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Comparison 1 Beta-carotene versus placebo, Outcome 1 Incidence of cataract.
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Comparison 1 Beta-carotene versus placebo, Outcome 2 Incidence of cataract extraction.
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Comparison 2 Vitamin C versus placebo, Outcome 1 Incidence of cataract.
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Comparison 2 Vitamin C versus placebo, Outcome 2 Incidence of cataract extraction.
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Comparison 3 Vitamin E versus placebo, Outcome 1 Incidence of cataract.
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Comparison 3 Vitamin E versus placebo, Outcome 2 Incidence of cataract extraction.
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Comparison 3 Vitamin E versus placebo, Outcome 3 Progression of cataract.
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Comparison 4 Beta-carotene plus vitamin E versus placebo, Outcome 1 Incidence of cataract 
extraction.
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Comparison 5 Vitamin C plus vitamin E versus placebo, Outcome 1 Incidence of cataract.
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Comparison 6 Beta-carotene plus vitamin C plus vitamin E versus placebo, Outcome 1 
Incidence of cataract extraction.
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Comparison 6 Beta-carotene plus vitamin C plus vitamin E versus placebo, Outcome 2 
Progression of cataract.
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Comparison 6 Beta-carotene plus vitamin C plus vitamin E versus placebo, Outcome 3 Loss 
of visual acuity.
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Table 1
Adverse events: hypercarotenodermia
Study ID Intervention n (%) Control n (%)
AREDS 2001 Beta-carotene + vitamin C + vitamin E 203 (8.6%) No antioxidants 146 (6.1%)
ATBC 1998 Beta-carotene + vitamin E 1281 (8.8%) No antioxidants 44 (0.3%)
REACT 2002 Beta-carotene + vitamin C + vitamin E 6 (7.4%) Placebo 0 (0%)
PHS I 2003 Beta-carotene 1745 (15.8%) Placebo 1535 (13.9%)
WHS 2004/8 Beta-carotene 2131 (10.7%) Placebo (includes vitamin E) 1944 (9.8%)
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CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
APC 2006
Methods Design: multicenter, parallel-arm RCT
Method of randomization: in blocks of 40
Method of allocation concealment: the placebo tablets were identical to active tablets in appearance and taste
Number randomized: 798
Exclusions after randomization: none
Number analyzed: 798; Group 1 = 398; Group 2 = 400
Masking: participants, study workers, investigators, biostatistician masked
Losses to follow-up: equal across treatment groups (personal communication)
Unit of analysis: analysis conducted for each eye separately
Participants Country: India
Age: range: 35 to 50 years
Gender (% female): 63.8% in Group 1, 58.5% in Group 2
Inclusion criteria: age 35 to 50 years, best corrected visual acuity of 20/40 or better in both eyes
Exclusion criteria: diabetes mellitus, intraocular surgery, radiation therapy, steroid therapy, active use of vitamin 
supplements, presence of congenital or traumatic cataract, active infectious keratitis, narrow anterior chamber angle
Interventions Treatment: vitamin C: 500 mg; vitamin E: 400 IU; beta-carotene: 15 mg 3 times a week
Control: placebo
Duration of treatment/length of follow-up: 5 years
Outcomes Primary:
  1. Change in nuclear opalescence from baseline using Lens Opacities Classification System III
Secondary:
  1. Change from baseline of nuclear color
  2. Change from baseline of cortical cataract
  3. Change from baseline of posterior subscapular cataract
  4. Change from baseline of best corrected spectacle visual acuity
  5. Change from baseline of refraction
  6. Failure of treatment defined as cataract progression to a point necessitating surgery or best corrected visual acuity of 
20/400 or worse
  7. Cataract surgery was offered if best corrected visual acuity decreased to 20/60 or worse or if decreased visual acuity 
caused problems with everyday functioning
Notes Study period: 5 years, 1999 to 2004
Study population: majority were middle class or lower in rural South India
Subgroup analysis: results stratified by age
Control group event rate: continuous outcomes were used
Equivalence of baseline characteristics: important baseline characteristics appear equally distributed
Quality of life indicators: none reported
Funding: Francis I. Proctor Foundation, Aravind Eye Hospital, Peierls Foundation, Jack and DeLoris Lange Foundation, 
Harper Inglis Trust
Risk of bias





Low risk Randomization was completed in blocks of 40 and within this 

















Unclear risk Data on losses to follow-up were unavailable, but were 
balanced across treatment groups

















Low risk Results were reported for outcomes described in the methods 
section
Other bias Low risk Met other parameters of quality that were assessed (see text)
AREDS 2001
Methods Design: multicenter, parallel-arm RCT
Method of randomization: computer-generated list (AREDS2 Advantage Electronic
Data Capture system (AdvantageEDCSM)).
Method of allocation concealment: the study tablets were identical in external and internal
appearance and taste
Number randomized: 4757
Exclusions after randomization: 128
Number analyzed: 4629; antioxidants = 2304; no antioxidants = 2325
Masking: participants, care providers and outcomes assessors masked
Losses to follow-up: 15% (includes those lost to follow-up and current smokers who
withdrew from the study)
Unit of analysis: individuals
Participants Country: USA
Age: median: 68 years; range: 55 to 80 years
Gender (% female): 56%
Inclusion criteria: best corrected visual acuity of 20/32 or better in at least one eye, at least one eye was free from eye 
disease that could complicate assessment of age-related macular degeneration, lens opacity progression or visual acuity
Exclusion criteria: illness or disorders such as history of cancer with a poor 7-year prognosis, major cardiovascular or 
cerebrovascular event within the last year or hemochromatosis
Interventions Treatment: vitamin C: 500 mg; vitamin E: 400 IU; beta-carotene: 15 mg daily 58% (n = 853) of those in the antioxidant 
group also received 80 mg of Zinc
Control: placebo
Duration of treatment/length of follow-up: average 6.3 years
Outcomes   1. Incidence of a cortical, nuclear or posterior subcapsular event
  2. Incidence of any lens event
  3. Best-corrected visual acuity
  4. Incidence of cataract surgery
  5. Incidence of any severe lens event
Outcomes were assessed at 6 months and annually
Some participants had 1 eye enrolled in the study and others had 2 study eyes
Notes Study period: 1992 to 2001
Study population: apparently well-nourished older cohort
Subgroup analysis: (a) on eyes with no or minimal opacity in one eye (n = 823), (b) no opacity in both eyes (n = 338) at 
baseline, (c) by type of cataract
Control group event rate: 34% for any lens event over 5 years
Equivalence of baseline characteristics: important baseline characteristics appear equally distributed. Approximately, 66% 
of AREDS participants chose to take CENTRUM, a commercially available multivitamin-mineral supplement, the use was 
balanced across treatment groups
Quality of life indicators: reported
Funding: National Eye Institute, National Institutes of Health, USA and Bausch and Lomb Inc
Risk of bias






















Low risk 90% had at least five years of follow-up. The losses to follow-
up were balanced across treatment groups

















Low risk Results were reported for outcomes described in the methods 
section
Other bias Low risk Met other parameters of quality that were assessed (see text)
ATBC 1998
Methods Design: 2 × 2 factorial RCT
Method of randomization: unavailable
Method of allocation concealment: unavailable
Number randomized: 29,133
Exclusions after randomization: 199
Number analyzed: 28,934
Masking: participants, care providers and outcomes assessors masked
Losses to follow-up: 28.4% in the alpha-tocopherol alone group to 29.4% in the beta-carotene alone group
Unit of analysis: individuals
Participants Country: Finland
Age: median: 57 years; range: 50 to 69 years
Gender: all men
Inclusion criteria: smokers of at least 5 cigarettes per day, absence of lung cancer as determined by an X-ray
Exclusion criteria: those with a history of cancer or serious disease limiting the ability to participate, those taking 
supplements of vitamin E, vitamin A or beta-carotene in excess of predefined doses, those on treatment with anticoagulants
Interventions Treatment:
(a) Alpha-tocopherol: 50 mg once daily
(b) Beta-carotene: 20 mg once daily
(c) Combination: once daily
Control: placebo
Duration of treatment/length of follow-up: 5 to 8 years; median: 5.7 years; 1,59,199 person-years
Outcomes   1. Incidence of cataract extraction
Outcome was identified from the National Hospital Discharge Registry using International Classification of Diseases codes
Notes Study period: 1986 to 1992
Study population: apparently healthy male smokers over 50 years
Subgroup analysis: age
Control group event rate: 1.44% over a median period of 5.7 years
Equivalence of baseline characteristics: important baseline characteristics appear equal.
There were fewer participants with diabetes in the placebo group
Quality of life indicators: none reported
Funding: National Public Health Institute of Finland and National Cancer Institute, National Institutes of Health, USA
Cataract extraction rates may differ by type of cataract, e.g. Posterior Subcapsular Cataract is treated early because of early 
decrease in vision
Risk of bias





















Unclear risk Losses to follow-up were greater than 28%, but were roughly 




Low risk Results were reported for outcomes described in the methods 
section
Other bias Low risk Met other parameters of quality that were assessed (see text)
PHS I 2003
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Methods Design: 2 × 2 factorial RCT
Method of randomization: computer-generated list of random numbers
Method of allocation concealment: study pills in the treatment arms were identical except for the active agent in the beta-
carotene group
Number randomized: 22,071
Exclusions after randomization: 1103; aspirin and beta-carotene: 286, aspirin and placebo: 278, beta-carotene and placebo: 
275, placebo only: 264
Number analyzed: 20,968; aspirin and beta-carotene = 5231, aspirin and placebo = 5242, beta-carotene and placebo = 
5244, placebo only = 5251
Masking: participants, care providers and outcomes assessors masked
Losses to follow-up: 99.2% provided information on morbidity after 11 years
Unit of analysis: individuals
Participants Country: USA
Age: mean: 52.6 years; range: 40 to 84 years
Gender: all male
Inclusion criteria: no history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke or transient 
cerebral ischemia
Exclusion criteria: current use of vitamin A supplement
Interventions Treatment:
(a) Beta-carotene: 50 mg on alternate days
(b) Aspirin: 325 mg on alternate days
Control: placebo, aspirin
Duration of treatment/length of follow-up: 12 years; range: 11.6 to 14.2 years
Outcomes 1. Incidence of age-related cataract over 12 years
2. Extraction of age-related cataract over 12 years
Outcome assessment was based on self reports confirmed by medical record review
Outcome assessed in the worse eye is used in the analysis
Notes Study period: 1982 to 1995
Study population: apparently healthy male medical professionals over 40 years
Subgroup analysis: (a) age (b) baseline smoking status
Control group event rate: 9.7% over 12 years for incident cataract
Equivalence of baseline characteristics: important baseline characteristics appear equally distributed
Quality of life indicators: none reported
Funding: National Institutes of Health, USA
Risk of bias









Low risk Study pills in the treatment arms were identical except for the 
















Low risk Results were reported for outcomes described in the methods 
section
Other bias Low risk Met other parameters of quality that were assessed (see text)
PHS II 2010
Methods Design: 2 × 2 × 2 × 2 factorial RCT
Method of randomization: computer-generated list of random numbers
Method of allocation concealment: study pills in the treatment arms were identical
Number randomized: 14,641
Exclusions after randomization: 3096; vitamin C and vitamin E: 771, vitamin C: 759, vitamin E: 773, placebo: 793
Number analyzed: 11,545; vitamin C and vitamin E: 2885, vitamin C: 2914, vitamin E: 2886, placebo: 2860
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Masking: participants, care providers and outcomes assessors masked
Losses to follow-up: 95.3% for morbidity and 97.7% for mortality
Unit of analysis: individuals
Participants Country: USA
Age: mean: 62 years, standard deviation: 7.9
Gender: all male
Inclusion criteria: no history of cancer (except non-melanoma skin cancer), cardiovascular disease, current liver disease, 
renal disease, peptic ulcer or gout
Exclusion criteria: unwillingness to avoid use of non-study supplements
Interventions Treatment:
(a) Vitamin C: 500 mg daily
(b) Vitamin E: 400 IU on alternate days
Control: placebo, vitamin C, vitamin E
Duration of treatment/length of follow-up: mean: 8 years
Outcomes 1. Incidence of age-related cataract over 12 years
2. Extraction of age-related cataract over 12 years
Outcome assessment was based on self reports confirmed by medical record review
Outcome assessed in the worse eye is used in the analysis
Notes Study period: 1997 to 2007
Study population: apparently healthy male medical professionals over 50 years
Subgroup analysis: (a) age (b) type of cataract and possible risk factors
Control group event rate: vitamin C: 10.1%, vitamin E: 10.3% over 8 years for incident cataract
Equivalence of baseline characteristics: important baseline characteristics appear equally distributed
Quality of life indicators: none reported
Funding: National Institutes of Health, USA, BASF Corporation
Risk of bias

























Low risk Results were reported for outcomes described in the methods 
section
Other bias Low risk Met other parameters of quality that were assessed (see text)
PPP 2001
Methods Design: 2 × 2 factorial RCT
Method of randomization: computer-generated randomization table
Method of allocation concealment: treatments were centrally assigned on telephone verification of the correctness of 
inclusion criteria with a separate computer-generated randomization table produced for each physician in random permuted 
blocks of 12
Number randomized: 4495
Exclusions post randomization: none
Number analyzed: 4495
Masking: open label trial. Clinical events were validated by an expert committee masked to treatment assignment, unclear 
if it extended to the outcome of interest in this review
Losses to follow-up: vitamin E group: 14, placebo group: 17
Unit of analysis: individuals
Participants Country: Italy
Age: mean: 64.5, standard deviation: 7.6 – 7.7
Gender: both male and female
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Inclusion criteria: age over 50 years with at least one of the major cardiovascular risk factors
Exclusion criteria: treatment with anti-platelet drugs, anti-inflammatory agents or anticoagulants, those with diseases with 
poor short-term prognosis
Interventions Treatment: vitamin E: 300 mg daily
Control: placebo
Duration of treatment/length of follow-up: mean of 3.6 years
Outcomes 1. Incidence of cataract surgery
Outcome assessment was validated by chart review
Notes Study period: 1993 to 1998
Study population: individuals with at least one risk factor for cardiovascular disease
Subgroup analysis: none
Control group event rate: 2.7%
Equivalence of baseline characteristics: important baseline characteristics appear equally distributed
Quality of life indicators: none reported
Funding: public source
Risk of bias

























Low risk Results were reported for outcomes described in the methods 
section
Other bias Low risk More than 13% of those randomized to vitamin E discontinued 
the medication, which is likely to bias the results towards no 
effect
REACT 2002
Methods Design: multicenter, parallel-arm RCT
Method of randomization: Efron’s biased coin method
Method of allocation concealment: those involved in preparing the randomization scheme were not associated with 
determining eligibility, administering the intervention or assessing the outcomes
Number randomized: 297
Exclusions after randomization: none (see number analyzed and losses to follow-up)
Number analyzed: completers of the study at 3 years: antioxidants = 81; placebo = 77
Masking: participants, care providers and outcomes assessors masked
Losses to follow-up: 66 (22%) after two years, 139 (47%) after 3 years, 261 (88%) after 4 years
Unit of analysis: individuals
Participants Country: USA and UK
Age: USA: mean: 64.7 years, standard deviation: 9.1 years, UK: mean: 67.9 years, standard deviation: 8.5 years
Gender (% female): USA: 62.4%, UK: 55.7%
Inclusion criteria: age, 40 years or older, at least at eye satisfying the following criteria: cataract extraction unlikely within 
the next 2 years, immature idiopathic senile cataract present in at least one or both eyes, logMAR acuity < = 0.5, no 
clinical signs of glaucoma
Exclusion criteria: use of vitamin supplements
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Interventions Treatment:
Beta-carotene: 6 mg; vitamin C: 250 mg; all-rac alpha-tocopherol acetate: 200 mg capsules 3 times per day
Control: placebo
Duration of treatment/length of follow-up: mean = 34 months; standard deviation: 12 months
Planned: 2 years, decided on 3 years used for the primary analysis (after the results of the interim analysis suggested a 
difference in effect)
Outcomes   1. Progression of cataract
  2. Logarithm of Minimum Angle of Resolution visual acuity
Outcomes were assessed approximately every 4 months
It is not clear whether outcome data were from the worse eye, or the average of both eyes
Notes Study period: 1990 to 1995
Study population: apparently healthy people over 40 years with some degree of age-related cataract
Subgroup analysis: (a) type of cataract (b) severity of cataract (based on % Pixels Opaque - Anterior)
Control group event rate: not applicable
Equivalence of baseline characteristics: those in the United Kingdom were slightly older, had lower serum proteins, poorer 
liver function, lower vitamin levels, less brunescent lenses and more nuclear and cortical opacification
Quality of life indicators: none reported
Funding: Industry: Hoffmann-La Roche
Risk of bias









Low risk Those involved in preparing the randomization scheme were 
not associated with determining eligibility, administering the 

















Low risk Results were reported for outcomes described in the methods 
section
Other bias Unclear risk Those in the United States were apparently healthier with less 
mature cataracts at baseline
VECAT 2004
Methods Design: parallel-arm RCT
Method of randomization: using permuted blocks
Method of allocation concealment: the allocation list was stored at a remote site and medication was dispensed in identical 
containers
Number randomized: 1204
Exclusions after randomization: 11
Number analyzed: vitamin E = 595, placebo = 598; completers: vitamin E = 443, placebo = 456
Masking: participants, care providers and outcomes assessors masked
Losses to follow-up: withdrawn: vitamin E: 78, placebo: 72; discontinued: vitamin E: 74, placebo: 70
Unit of analysis: individuals
Participants Country: Australia
Age: mean: 65.67 years; range: 55 to 80 years
Gender (% female): 56%
Inclusion criteria: age between 55 and 80 years
Exclusion criteria: prior cataract surgery, advance cataract in both eyes, glaucoma, known sensitivity to vitamin E, long-
term treatment with steroids and anti-coagulants
Interventions Treatment:
(a) Vitamin E, 500 IU natural vitamin E in soybean oil daily
Control: placebo
Duration of treatment/length of follow-up: 4 years
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Outcomes   1. Incidence of cataract (nuclear, cortical and posterior subcapsular, clinical grading and digital assessment) over 4 years
  2. Cataract extraction over 4 years
  3. Progression of cataract (nuclear, cortical and posterior subcapsular, clinical grading and digital assessment) over 4 
years
Outcomes were assessed annually
Incidence and prevalence were assessed using data from the worse eye, but progression rates were not derived from the eye 
with the most advanced cataract change at baseline
Notes Study period: 1995 to 2000
Study population: apparently healthy people over 55 years with some degree of age-related cataract
Subgroup analysis: (a) type of cataract
Control group event rate: 16.7% over 4 years for incident cataract
Equivalence of baseline characteristics: the vitamin E group had a statistically significant greater number of cases of 
cortical and any cataract at baseline. Other baseline characteristics
appear equally distributed
Quality of life indicators: assessed using health-related quality of life SF-36 and visual function 14 questionnaires. Data not 
reported
Funding: National Health and Medical Research Council of Australia and other foundations
Risk of bias





Low risk Randomization schedule was prepared by a biostatistician using 




Low risk The allocation list was stored at a remote site and medication 












Unclear risk Losses to follow-up were greater than 23%, but were roughly 




Low risk Results were reported for outcomes described in the methods 
section
Other bias Unclear risk The vitamin E group had a statistically significant greater 
number of cases of cortical and any cataract at baseline and 
these were excluded from the analysis for incidence of cataract
WHS 2004/8
Methods Design: 2 × 2 × 2 factorial RCT
Method of randomization: computer-generated list of random numbers




Beta-carotene component: 3141; beta-carotene: 1534; placebo: 1607
Vitamin E component: 2201; vitamin E: 1137; placebo: 1064
Number analyzed:
Beta-carotene component: 36,735; beta-carotene: 18,405; placebo: 18,330
Vitamin E component: 37,675; vitamin E: 18,800; placebo: 18,875
Masking: participants, care providers and outcome assessors masked
Losses to follow-up: the beta-carotene component was terminated early and for the vitamin E component, mortality and 
morbidity follow-up were 97.2% and 99.4% respectively
Unit of analysis: individuals
Participants Country: USA
Age: mean: beta-carotene component: 53.2 years; vitamin E component: 54.1 years; range: 45 years and older
Gender: all female
Inclusion criteria: no history of cancer (except non melanoma skin cancer), coronary heart disease or cerebrovascular 
disease
Exclusion criteria: see above
Interventions Treatment:
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(a) Beta-carotene, 50 mg on alternate days
(b) Vitamin E: 600 IU on alternate days
(c) Aspirin 100 mg on alternate days
Control: placebo, aspirin, beta-carotene, vitamin E
Duration of treatment/length of follow-up:
Beta-carotene component: median: 2.1 years; range: 0.00 to 2.72 years
Vitamin E component: average: 9.7 years
Compliance:
Beta-carotene component: 87% reported taking at least 2/3rd of study capsules; vitamin E component: 78.9% reported 
taking at least 2/3rd of study capsules at 5 years and 71.6% at 10 years
Outcomes   1. Incidence of age-related cataract
  2. Extraction of age related cataract
Outcomes were assessed every 6 months for first year and annually thereafter
Outcome assessment was based on self reports confirmed by medical record review
Outcome assessed in the worse eye is used in the analysis
Notes Study period: 1993 to 2004
Study population: apparently health women health professionals
Subgroup analysis:
Beta-carotene component: (a) age, (b) baseline smoking status
Vitamin E component: (a) age, (b) type of cataract
Control group event rate:
Beta-carotene component: 0.007% over 2.1 years for incident cataract
Vitamin E component: 6.5% over 9.7 years for incident cataract
Equivalence of baseline characteristics: important baseline characteristics appear equally
distributed
Quality of life indicators: none reported
Funding: National Institutes of Health, USA
Risk of bias









Low risk Study pills in the treatment arms were identical except for the 












Low risk Morbidity follow-up rates for the beta-carotene and vitamin E 




Low risk Results were reported for outcomes described in the methods 
section
Other bias Low risk Met other parameters of quality that were assessed (see text)
RCT: randomized controlled trial
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AREDS 2000 Article regarding zinc as the exposure in the AREDS study
Asensio-Sanchez 2002 Article in Spanish: letter regarding results for age-related macular degeneration in the AREDS study
Augustin 2002 Article in German: comment regarding the AREDS study
CTNS 2008 The intervention is a multivitamin-mineral supplement CENTRUM. As it contains a combination of multiple 
vitamins and minerals, it is not possible to tease out the effects of the major antioxidant vitamins: beta-carotene, 
vitamin C and vitamin E, either singly or in combination, which is the focus of this review
Diplock 1994 Review on antioxidants and their role in disease prevention
Floren 1994 Review on the pathophysiology of antioxidants in relation to cataract
Leske 1997 Barbados Eye Study: not an RCT
Li 1993 Article in Chinese: reporting the preliminary results of the Linxian study
LINXIAN 1993 Though an RCT, the analysis was conducted in a non-random sample at the end of the trial
Mares-Perlman 2000 Beaver Dam Eye Study: not an RCT
Olmedilla 2003 Sample size of the study: 17; unit of analysis: eyes; high loss to follow-up after 1 year
Phakan 1982 Article in German: duration of treatment 9 months
Sackett 2002 Review on the results of the AREDS study
Schutt 2002 Article in German: discussion regarding recommendations based on the AREDS study
Seddon 1994 Physicians’ Health Study I (PHS I): the intervention examined in this report, multivitamin supplements, was not 
randomly assigned
Seth 1999 Duration of intervention: 30 days
Sharma 1989 Average length of follow-up: 9 to 11 months in the study groups
Shiriaeva 1987 Article in Russian: Not an RCT
SUVIMAX 1998 Principal Investigator reported that ’eye’ outcomes will not be analyzed
Teikari 1997 Article examining an end of trial random sample of participants in the ATBC study
Zrenner 2001 Article in German: regarding status of recommendations regarding vitamin A in relation to hereditary retinal 
degeneration
AREDS: Age-Related Eye Disease Study; ATBC: Alpha-tocopherol Beta-carotene Study; RCT: randomized controlled trial
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Characteristics of ongoing studies [ordered by study ID]
NCT01142960
Trial name or title Effects of vitamin C and Lycium barbarum supplements on the progression of senile cataract in Hong Kong Chinese 
population
Methods Design: parallel assignment RCT
Participants Country: Hong Kong, China
Age: 60 to 75 years
Gender: male and female
Inclusion criteria: unlikely to have cataract surgery within 3 years, present of mild to moderate cataract, no ocular 
anomalies or use of ocular drugs
Exclusion criteria: diabetes mellitus, renal failure, use of anticoagulants, alcoholism, regular use of multivitamin, 
mineral or other antioxidant supplements
Interventions Treatment: vitamin C: 500 mg daily
Control: placebo
Duration of treatment/length of follow-up: 3 years
Outcomes 1. Lens opacity classification system III (LOCS III)
2. Visual acuity
Starting date July 2010
Contact information Chi-wai Do, PhD; socwdo@inet.polyu.edu.hk
Notes Study population: apparently healthy between 60 and 75 years
Funding: the Hong Kong Polytechnic University
WACS
Trial name or title The Women’s Antioxidant and Cardiovascular Study (WACS)
Methods Design: 2 × 2 × 2 × factorial RCT
Method of randomization: computer-generated list of random numbers
Method of allocation concealment: study pills in the treatment arms were identical
Number randomized: 8171
Number analyzed: pending analysis
Masking: participants, care providers and outcomes assessors masked
Losses to follow-up: pending analysis
Unit of analysis: pending analysis
Participants Country: USA
Age: mean: 60.6 years, standard deviation: 8.8
Gender: all female
Inclusion criteria: 40 years or older, postmenopausal or had no intention of becoming pregnant, self reported history of 
cardiovascular disease or had at least 3 cardiovascular risk factors
Exclusion criteria: self reported history of cancer (excluding non-melanoma skin cancer), serious non cardiovascular 
illness, use of anticoagulants, unwilling to forgo antioxidant vitamin supplementation outside the trial
Interventions Treatment: (a) beta-carotene: 50 mg every other day; (b) vitamin C: 500 mg daily; (c) vitamin E: 600 IU every other day
Control: placebo
Duration of treatment/length of follow-up: 9.4 years, range: 8.3 to 10.1 years
Outcomes 1. Incidence of cataract
2. Incidence of cataract extraction
3. Loss of visual acuity
Starting date 1995
Contact information Dr. JoAnn E. Manson MD DrPH
900 Commonwealth Avenue East
Boston MA 02215-1204
Notes Study period: 1995 to 2005
Study population: women with at least 3 cardiovascular risk factors; secondary prevention trial component of the 
Women’s Health Study (WHS)
Funding: National Heart, Lung and Blood Institute
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